Aim Immunotech Stock Analysis
| AIM Stock | USD 1.23 0.17 16.04% |
IPO Date 12th of July 1996 | 200 Day MA 4.1617 | 50 Day MA 1.3186 | Beta 1.237 |
AIM ImmunoTech holds a debt-to-equity ratio of 0.02. At this time, AIM ImmunoTech's Debt Ratio is very stable compared to the past year. AIM ImmunoTech's financial risk is the risk to AIM ImmunoTech stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
AIM ImmunoTech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. AIM ImmunoTech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps AIM Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect AIM ImmunoTech's stakeholders.
For many companies, including AIM ImmunoTech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for AIM ImmunoTech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, AIM ImmunoTech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.7248 | Enterprise Value Ebitda 0.4928 | Price Sales 35.9822 | Shares Float 2.7 M | Wall Street Target Price 13.986 |
Given that AIM ImmunoTech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which AIM ImmunoTech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of AIM ImmunoTech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, AIM ImmunoTech is said to be less leveraged. If creditors hold a majority of AIM ImmunoTech's assets, the Company is said to be highly leveraged.
At this time, AIM ImmunoTech's Common Stock Shares Outstanding is very stable compared to the past year. As of the 6th of February 2026, Common Stock is likely to grow to about 86.7 K, while Liabilities And Stockholders Equity is likely to drop about 9.4 M. . As of the 6th of February 2026, Price To Sales Ratio is likely to drop to 72.00. In addition to that, Price Earnings Ratio is likely to drop to -0.61. AIM ImmunoTech is undervalued with Real Value of 4.39 and Target Price of 13.99. The main objective of AIM ImmunoTech stock analysis is to determine its intrinsic value, which is an estimate of what AIM ImmunoTech is worth, separate from its market price. There are two main types of AIM ImmunoTech's stock analysis: fundamental analysis and technical analysis.
The AIM ImmunoTech stock is traded in the USA on AMEX Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. AIM ImmunoTech is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. AIM Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. AIM Stock Analysis Notes
The company recorded a loss per share of 21.17. AIM ImmunoTech last dividend was issued on the 11th of June 2019. The entity had 1:100 split on the 12th of June 2025. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Aim Immunotech operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 21 people. For more info on AIM ImmunoTech please contact Esq JD at 352 448 7797 or go to https://aimimmuno.com.AIM ImmunoTech Investment Alerts
| AIM ImmunoTech generated a negative expected return over the last 90 days | |
| AIM ImmunoTech has high historical volatility and very poor performance | |
| AIM ImmunoTech may become a speculative penny stock | |
| AIM ImmunoTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 170 K. Reported Net Loss for the year was (17.32 M) with profit before taxes, overhead, and interest of 17 K. | |
| AIM ImmunoTech has about 1.7 M in cash with (14.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Latest headline from news.google.com: Pricey healthcare stocks with halting momentum - low momentum and high valuation - Seeking Alpha |
AIM Largest EPS Surprises
Earnings surprises can significantly impact AIM ImmunoTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-13 | 2022-03-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-11-15 | 2021-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-05-17 | 2021-03-31 | -0.09 | -0.08 | 0.01 | 11 |
AIM Market Capitalization
The company currently falls under 'Nano-Cap' category with a total capitalization of 4.03 M.AIM Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.31) | (3.15) | |
| Return On Capital Employed | 19.20 | 20.16 | |
| Return On Assets | (2.31) | (2.20) | |
| Return On Equity | 11.79 | 12.38 |
Management Efficiency
AIM ImmunoTech has Return on Asset of (0.9542) % which means that on every $100 spent on assets, it lost $0.9542. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (31.3891) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AIM ImmunoTech's Return On Capital Employed is very stable compared to the past year. As of the 6th of February 2026, Return On Equity is likely to grow to 12.38, though Return On Tangible Assets are likely to grow to (3.15). At this time, AIM ImmunoTech's Non Current Assets Total are very stable compared to the past year. As of the 6th of February 2026, Intangible Assets is likely to grow to about 3.1 M, while Other Current Assets are likely to drop about 217.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.71) | (2.58) | |
| Tangible Book Value Per Share | (8.04) | (7.64) | |
| Enterprise Value Over EBITDA | (0.68) | (0.71) | |
| Price Book Value Ratio | (9.75) | (9.26) | |
| Enterprise Value Multiple | (0.68) | (0.71) | |
| Price Fair Value | (9.75) | (9.26) | |
| Enterprise Value | 2.9 M | 2.8 M |
The operational strategies employed by AIM ImmunoTech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 6th of February, AIM ImmunoTech shows the Mean Deviation of 4.54, coefficient of variation of (1,011), and Risk Adjusted Performance of (0.07). AIM ImmunoTech technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm AIM ImmunoTech standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if AIM ImmunoTech is priced adequately, providing market reflects its regular price of 1.23 per share. Given that AIM ImmunoTech is a hitting penny stock territory we recommend to closely look at its jensen alpha.AIM ImmunoTech Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
AIM ImmunoTech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AIM ImmunoTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on AIM ImmunoTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AIM ImmunoTech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AIM ImmunoTech Outstanding Bonds
AIM ImmunoTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AIM ImmunoTech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AIM bonds can be classified according to their maturity, which is the date when AIM ImmunoTech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ACACN 36 15 MAR 27 Corp BondUS009090AA91 | View | |
| ACACN 525 01 APR 29 Corp BondUS00909DAA19 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
AIM ImmunoTech Predictive Daily Indicators
AIM ImmunoTech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AIM ImmunoTech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
AIM ImmunoTech Forecast Models
AIM ImmunoTech's time-series forecasting models are one of many AIM ImmunoTech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AIM ImmunoTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.AIM ImmunoTech Bond Ratings
AIM ImmunoTech financial ratings play a critical role in determining how much AIM ImmunoTech have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for AIM ImmunoTech's borrowing costs.| Piotroski F Score | 5 | Healthy | View |
| Beneish M Score | (4.93) | Unlikely Manipulator | View |
AIM ImmunoTech Debt to Cash Allocation
Many companies such as AIM ImmunoTech, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
AIM ImmunoTech has 2.94 M in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. AIM ImmunoTech has a current ratio of 13.93, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Nevertheless, prudent borrowing could serve as an effective mechanism for AIM to finance growth opportunities yielding strong returns. AIM ImmunoTech Total Assets Over Time
AIM ImmunoTech Assets Financed by Debt
The debt-to-assets ratio shows the degree to which AIM ImmunoTech uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.AIM ImmunoTech Debt Ratio | 41.0 |
AIM ImmunoTech Corporate Bonds Issued
AIM Short Long Term Debt Total
Short Long Term Debt Total |
|
About AIM Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how AIM ImmunoTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AIM shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AIM ImmunoTech. By using and applying AIM Stock analysis, traders can create a robust methodology for identifying AIM entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (117.16) | (123.02) | |
| Operating Profit Margin | (133.75) | (140.44) | |
| Net Loss | (117.16) | (123.02) | |
| Gross Profit Margin | 0.94 | 0.99 |
Current AIM Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AIM analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AIM analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 13.99 | Strong Buy | 2 | Odds |
Most AIM analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand AIM stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of AIM ImmunoTech, talking to its executives and customers, or listening to AIM conference calls.
AIM Stock Analysis Indicators
AIM ImmunoTech stock analysis indicators help investors evaluate how AIM ImmunoTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AIM ImmunoTech shares will generate the highest return on investment. By understating and applying AIM ImmunoTech stock analysis, traders can identify AIM ImmunoTech position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 5.4 M | |
| Common Stock Shares Outstanding | 560.2 K | |
| Total Stockholder Equity | -1.3 M | |
| Total Cashflows From Investing Activities | 4.7 M | |
| Property Plant And Equipment Net | 726 K | |
| Cash And Short Term Investments | 4 M | |
| Cash | 1.7 M | |
| Accounts Payable | 6.4 M | |
| Net Debt | 1.2 M | |
| 50 Day M A | 1.3186 | |
| Total Current Liabilities | 9.5 M | |
| Other Operating Expenses | 19.9 M | |
| Non Current Assets Total | 4.4 M | |
| Non Currrent Assets Other | 1.1 M | |
| Stock Based Compensation | 686 K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (21.17) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.